TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Oximetry and Neurocognitive Functions in Cardiosurgical Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with coronary artery disease undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass~Exclusion Criteria:~* Who refuse to participate~* Previous stroke~* Preexisting psychiatric disease~* Significant carotid stenosis~* Ejection fraction below 25%~* Reoperations~* Emergent surgery~* Dialysis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- INVOS (Type: ACTIVE_COMPARATOR): INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
- CONTROL (Type: NO_INTERVENTION): The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* infants aged 6 to 12 weeks~* born in Brest District, France~* born between Feb 01, 2007 and Nov 19, 2009~Exclusion Criteria:~* contraindication to rotavirus vaccine

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Cohort of vaccinated infants against rotavirus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated study informed consent~* Class I or Class IIa pacemaker indication~* Geographically stable and available for follow-up at the center for the length of the study~* Age greater than 18~* To be implanted with Adapta dual chamber pacemaker~Exclusion Criteria:~* Unwillingness or inability to give written informed consent to participate in the Study~* Patient with a previously implanted pacemaker/Implantable Cardioverter-Defibrillator (ICD)/Cardiac Resynchronization Therapy (CRT) device~* Life expectancy of less than one year~* Patient has a mechanical tricuspid heart valve~* Medical conditions that preclude the testing requirement by the protocol or limit study participation~* Patient has persistent 3rd degree atrioventricular (AV) block~* Patient has persistent atrial fibrillation (AF)~* Patient has neurogenic syncope~* Patient has carotid sinus syndrome~* Patient has hypertrophic obstructive cardiomyopathy~* Inclusion in another clinical trial or study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Managed Ventricular Pacing (Type: ACTIVE_COMPARATOR): Managed Ventricular Pacing group: programmed on
- Search AV+ (Type: ACTIVE_COMPARATOR): Search AV+: programmed on

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Written, informed consent~* 18 years of age or older~* Current diagnosis of opioid dependence, based on Diagnostic and Statistical Manual of Mental Health Disorders, 4th Ed. (DSM-IV-TR) criteria~* Voluntarily seeking treatment for opioid dependence~* Completing or recently completed up to 30 days of inpatient treatment for opioid detoxification, and off all opioids (including buprenorphine and methadone) for at least 7 days~* Noncustodial, stable residence and phone, plus 1 contact with verifiable address and phone~* Significant other (eg, spouse, relative) willing to supervise compliance with the study visit schedule and procedures~* Agree to use contraception for study duration if of childbearing potential~Primary Exclusion Criteria:~* Pregnancy or lactation~* Clinically significant medical condition or observed abnormalities (eg: physical exam, electrocardiogram (ECG), lab and/or urinalysis findings)~* Positive naloxone challenge test at randomization (Day 0)~* Evidence of hepatic failure including: ascites, bilirubin \>10% above upper limit of normal (ULN) and/or esophageal variceal disease~* Past or present history of an acquired immunodeficiency syndrome (AIDS)-indicator disease in HIV-infected subjects~* Active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase(ALT) \>3xULN~* Current major depression with suicidal ideation, psychosis, bipolar disorder, or any psychiatric disorder that would compromise ability to complete the study~* Recent history (within 6 months prior to screening) of suicidal ideation or attempt~* Dependence within prior year based on DSM-IV-TR, to any drugs other than prescription opioids or heroin, caffeine, marijuana, or nicotine~* Active alcohol dependence within prior 6 months~* Current alcohol use disorder that would, in the Investigator's opinion, preclude successful completion of the study~* Positive urine drug test for cocaine, benzodiazepines, or amphetamines at screening~* Use of oral naltrexone for 7 consecutive days within 60 days prior to screening~* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIVITROL® 380 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Qidong Hepatitis B Intervention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~all infants born in Qidong between September 1983 and November 1990~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Hypogonadal males~2. Screening testosterone \<300 ng/dL~Exclusion Criteria~1. Smokers~2. Previous history of or current or suspected prostate or breast cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Testosterone Gel 1.62%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 -60 years, of either sex with the clinical diagnosis of bipolar disorder (DSM V) who are on maintenance lithium therapy for ≥ 1month and ≤ 6 months.~* Patients with normal serum sodium level (135 -145 mEq/L) and serum lithium in the optimum therapeutic range (\<0.6 mEq/ L or \>0.8 mEq/ L) .~Exclusion Criteria:~* Patients with comorbidities like other psychiatric disorder s, organicity, substance abuse, personality disorder, intellectual disability and other neurotic disorders .~* Patients with any renal, cardiovascular, neurologica l, endocrinal and hepatic dysfunction.~* Patients suffering from diarrhoea, dehydration~* History of any invasive neurosurgical/ non -invasive neuropsychiatric procedure.~* Medication history of psychoactive or central nervous system depressant drugs.~* Patients who are on NSAIDs, ACE inhibitors, antiarrhythmics, diuretics and neuromuscular blocking agents .~* Pregnant and nursing women .~* Patients with drug/alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lithium carbonate (Type: ACTIVE_COMPARATOR): Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
- Add-on Sodium chloride (Type: EXPERIMENTAL): Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ambulatory adults aged 50 years and older~2. Medically stable, as determined by medical history and targeted physical examination based on medical history, if appropriate~3. Able to understand and comply with planned study procedures~4. Provides written informed consent prior to initiation of any study procedure.~Exclusion Criteria:~1. Known contraindication to either study vaccine (see product package inserts)~2. Receipt of any other influenza or other vaccine within 30 days prior to enrollment in this study.~3. Receipt of any new medication within 30 days prior to enrollment in this study~4. Plans to participate in any investigation involving an investigational product during this study.~5. Pre-existence of atopic dermatitis or any other cutaneous disorder that could complicate the evaluation of potential primary endpoints.~6. Any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation of clinical data.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Flublok (Type: ACTIVE_COMPARATOR): Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
- Afluria (Type: PLACEBO_COMPARATOR): Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* T-cell lymphoma (excluding mycosis fungoides)~* WHO performance status 0-2~* measurable lesions~* acceptable hematological and biochemical parameters~* previously treated OR untreated but not suitable for standard therapy~Exclusion Criteria:~* pregnant~* HIV~* viral hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To have participated in the single-dose clinical study (EF099) previously performed, with the clinical response being considered as satisfactory by the investigator~* The patient should be a male or female, aged between 18 and 60 years old~* Have a medical history consistent with lactose intolerance, confirmed by the test of hydrogen in the expired air~* The female patients should agree to use birth control methods during the study participation~* To be able to meet the study instructions and all the visits required~* To give a free consent to participate in the study and sign the informed consent form (ICF).~Exclusion Criteria:~* Smoking~* Secondary hypolactasia~* Gastrointestinal inflammatories diseases - present diverticular disease, diabetic gastropathy or neoplasias~* Colonoscopy or colon cleaning procedure 4 weeks before the start of study~* Latrogenic: unnoticed intake of laxatives in over-the-counter drugs or alternative medicine, intake of cereal bran or probiotics~* Diagnosis of HIV, immunodepression of any origin, or cancer under treatment.~* Diagnosis of other comorbidity that, at the investigator's discretion, may compromise the study participation (e.g., systemic infection during the study or use of antibiotics in the last 4 weeks, diabetes mellitus, uncontrolled hypertension or renal failure),~* Hypersensitivity or previous laboratory or clinical adverse event related to the use of lactase or any of the components of the formulations used in the study~* Incapacity to understand and complete the study questionnaires, including the questions that require the use of the Visual Analogue Scale and ICF~* Pregnancy or lactation~* Use of alcohol, exceeding 3 doses daily~* Participation in another clinical study on the last 12 months~* Patient having some chronic pulmonary disease that, in the investigator's opinion, may harm or interfere with the expired hydrogen test (e.g., cystic fibrosis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lactase EUF (Type: EXPERIMENTAL): 1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
- Lactase Ref (Type: ACTIVE_COMPARATOR): 1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.~* Presence of measurable disease per RECIST v1.1.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~Exclusion Criteria:~* Laboratory and medical history parameters not within the Protocol-defined range.~* Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.~* Previous radiotherapy within 2 weeks of starting study therapy.~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.~* Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.~* Receipt of a live vaccine within 30 days of planned start of study therapy.~* Active infection requiring systemic therapy.~* Subjects who have any active or inactive autoimmune disease or syndrome.~* Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
- Treatment Group B (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
- Treatment Group C (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + carboplatin and paclitaxel
- Treatment Group D (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
- Treatment Group E (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + cyclophosphamide
- Treatment Group F (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
- Treatment Group G (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WALANT Technique (Wide Awake Local Anesthesia No Tourniquet) for Carpal Tunnel Release.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing endoscopic carpal tunnel release~* Consent for participation~* Affiliation to a social security system~Exclusion Criteria:~* Chronic pain syndrome or fibromyalgia~* Contraindication for locoregional anesthesia~* ASA 4~* Pregnant or breastfeeding women~* Patients under protection of the adults(guardianship, curators or safeguard of justice)~* Communication difficulties or neuropsychiatric disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CONTROL (Type: ACTIVE_COMPARATOR): Troncular blocks using a long-acting LA + Tourniquet
- WALANT (Type: EXPERIMENTAL): Troncular blocks using a long-acting LA + WALANT technique using a short-term LA with epinephrine a vasoconstrictor agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Uncomplicated falciparum or vivax malaria or mixed species infection, as confirmed in a peripheral blood slide.~* No signs of severe malaria~* Age over three months.~* Non-pregnant, (test for β-HCG in women of child-bearing age).~* Weight ≥5 kg~* Willingness to participate and written informed consent provided by the patient or in case of children by attending guardians/parents.~* Not enrolled in any other investigational drug study in the previous month~Exclusion Criteria:~* Clinical or laboratory features suggesting severe malaria.~* Known cardiac, renal, hepatic or other severe disease, or requirement for hospital treatment~* Recurrent vomiting.~* Not eligible for follow-up.~* Lactating mother~* Hyperparasitemia of P. falciparum \> 100,000/µL~* Treatment with Artesunate or Chloroquine in the past one month, Fansidar in the past one and the half months and Artekin in past 3 months.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artekin (Type: EXPERIMENTAL): Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
- Standard treatment (Type: ACTIVE_COMPARATOR): The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete